MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • 2026 International Congress

    Efficacy of Aripiprazole on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis

    I. Serag (Mansoura, Egypt)

    Objective: To systematically evaluate and quantitatively synthesize evidence on the effect of Aripiprazole on cognitive functions in patients with Parkinson’s disease. Background: Cognitive impairment is…
  • 2026 International Congress

    Remotely Administered Reaction Time Correlates in Progressive Supranuclear Palsy

    T. Siejka, K. Bertram, H. Butzkueven, D. Darby, A. Brodtmann (Melbourne, Australia)

    Objective: To evaluate the cross-sectional associations of remotely administered reaction time (RT) in PSP. Background: PSP causes cognitive dysfunction, with severe deficits in psychomotor speed,…
  • 2026 International Congress

    Cognitive Impairment and Neuropsychiatric Manifestations in Parkinson’s disease in Africa: A Systematic Review of Evidence

    M. Njohjam, F. Niakam, M. Ngoule (Dakar, Senegal)

    Objective: To critically appraise and synthesize evidence on the prevalence and clinical correlates of cognitive impairment and neuropsychiatric manifestations among patients with Parkinson’s disease in…
  • 2026 International Congress

    The Parkinson’s Impact Project: A Multimodal Longitudinal Study of Disease Development and Progression at the 23andMe Research Institute

    M. Kmiecik, L. Norcliffe-Kaufmann, W. Xu, C. Weldon, V. Tran, A. Guan, M. Mcintyre, S. Aslibekyan (Palo Alto, USA)

    Objective: Characterize the interactions between lifestyle, environmental, and genetic exposures on susceptibility to Parkinson’s disease (PD) and progression rates through a scalable remote web-based multimodal…
  • 2026 International Congress

    Digital Assessment of Cognitive Function in Parkinson’s Disease: Preliminary Feasibility and Validity Data

    M L. Nasi, E. Fiorenzato, L. Weis, F. Vianello, D. Lupi, A. Antonini, R. Biundo (Padova, Italy)

    Objective: To evaluate the feasibility, usability and convergent validity of a digital neuropsychological assessment battery designed to detect cognitive impairment in Parkinson’s Disease (PD). Background:…
  • 2026 International Congress

    Distinct Neurostructural, Cognitive, and Neuropsychiatric Associations of Plasma p-tau217, and Aβ42/40 in Parkinson’s Disease and Aging Cohorts

    E. Fiorenzato, S. Cauzzo, G. Musso, R. Biundo, C. Ceolin, C. Fogliano, C. Cosma, W. Meissner, V. Misenti, S. Moz, ML. Nasi, F. Vianello, R. Manara, M. Montagnana, G. Sergi, A. Antonini (Padova, Italy)

    Objective: To investigate associations between plasma biomarkers of Alzheimer’s disease (AD) pathology [phosphorylated-tau-217 (p-tau217), amyloid-beta-42/40 (Aβ42/40)], neurodegeneration [neurofilament light chain (NfL)], and neuroinflammation [glial fibrillary…
  • 2026 International Congress

    Impact of Vitamin D Supplementation on Cognitive Function, Quality of Life, and Dyskinesia in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    C. Perera, A. Pathirage, K. Muhunthan, S. Jayakody, C. Arambepola, T. Chang (Colombo, Sri Lanka)

    Objective: To evaluate the impact of vitamin D supplementation on cognitive outcomes, quality of life and dyskinesia severity in PD through a systematic review and…
  • 2026 International Congress

    Safety and Feasibility of Repetitive Transcranial Magnetic Stimulation in Dementia with Lewy Bodies: An Ongoing Proof-of-Concept Study

    K. Baik, M. Park (Seoul, Republic of Korea)

    Objective: To investigate the safety and potential cognitive benefits of repetitive transcranial magnetic stimulation (rTMS) in patients with dementia with Lewy bodies (DLB) using a…
  • 2026 International Congress

    Efficacy of Novel Antipsychotic Agents on Cognitive Functions in Parkinson’s Disease: A Systematic Review and Meta-analysis of 2,533 Patients

    I. Serag (Mansoura, Egypt)

    Objective: To systematically evaluate and quantitatively synthesize evidence on the effects of novel antipsychotic agents (Clozapine, Olanzapine, Risperidone, and Aripiprazole) on cognitive domains in Parkinson’s…
  • 2026 International Congress

    Expanding the Childhood Spectrum of Dentatorubral–pallidoluysian Atrophy: Neuropsychiatric and Motor Phenotypes in Four Siblings

    M. Siegel, I. Malaty, A. Ramirez-Zamora (Gainesville, USA)

    Objective: We aim to characterize the striking clinical heterogeneity of movement, epileptic, and neuropsychiatric symptoms in a cohort of four siblings with genetically confirmed DRPLA.…
  • 1
  • 2
  • 3
  • …
  • 141
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley